Mangrove Partners’s Inhibrx INBX Stock Holding History

Mangrove Partners’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,531	Closed	-$372K	–	508
2026 Q1	$372K	Buy	+5,531	New	+$410K	0.03%	235

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mangrove Partners's INBX Position: Q2 2026 in Review

Mangrove Partners sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 5,531 shares — an estimated $372K sold.

Mangrove Partners first reported a position in INBX in Q1 2026 and held it in 1 quarter. The position peaked at $372K in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Mangrove Partners reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
Mangrove Partners sold 5,531 Inhibrx shares in Q2 2026, an estimated $372K.
Mangrove Partners first reported a position in Inhibrx in Q1 2026 and held it in 1 quarter.
Mangrove Partners's Inhibrx position peaked at $372K in Q1 2026.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.